

JA



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/085,047	03/01/2002	Bozidar Ferek-Petric	P-8158.03 DIV2	1360
27581	7590	02/22/2005	EXAMINER	
MEDTRONIC, INC. 710 MEDTRONIC PARKWAY NE MS-LC340 MINNEAPOLIS, MN 55432-5604			OROPEZA, FRANCES P	
			ART UNIT	PAPER NUMBER
			3762	

DATE MAILED: 02/22/2005

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary

Application No.

10/085,047

Applicant(s)

FEREK-PETRIC, BOZIDAR

Examiner

Frances P. Oropeza

Art Unit

3762

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --
Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on 11/15/04 (Amendment).
2a) ☒ This action is **FINAL**. 2b) ☐ This action is non-final.
3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 40-42 is/are pending in the application.
4a) Of the above claim(s) _____ is/are withdrawn from consideration.
5) ☐ Claim(s) _____ is/are allowed.
6) ☒ Claim(s) 40-42 is/are rejected.
7) ☐ Claim(s) _____ is/are objected to.
8) ☐ Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
10) ☒ The drawing(s) filed on 15 November 2004 is/are: a) ☒ accepted or b) ☐ objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
a) ☐ All b) ☐ Some * c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
2. ☐ Certified copies of the priority documents have been received in Application No. _____.
3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- 1) ☒ Notice of References Cited (PTO-892)
2) ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948)
3) ☐ Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08)
Paper No(s)/Mail Date _____.
4) ☐ Interview Summary (PTO-413)
Paper No(s)/Mail Date _____.
5) ☐ Notice of Informal Patent Application (PTO-152)
6) ☐ Other: _____.

DETAILED ACTION

Response

1. The Applicant amended the claims in the response filed 11/15/04, hence the rejection of record is withdrawn and a new rejection established in the subsequent paragraph.

Claim Rejections - 35 USC § 112

2. The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

3. Claim 41 is rejected under 35 U.S.C. 112, first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter that was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention.

The Examiner is unable to find in the specification the limitations in parenthesis:

..."mathematical" integral of "at least one of the blood flow signal and the sensed electrical signal". The specification does not define a "mathematical" integral nor how it is determined. In addition, specification page 16, line 24, indicates only the integral of the blood flow rate signal is calculated. New matter may not be added at this point in the prosecution. Appropriate correction is required.

Claim Rejections - 35 USC § 103

4. Claim 41 is rejected under 35 U.S.C. 103(a) as being unpatentable over Soykan et al. (US 6206914) in view of Nappholz et al. (US 5113869).

Soykan et al. teach an implantable system that monitors ECG signals and coronary sinus blood flow signals to detect ischemia and provide treatment. The treatment can be patient initiated (abstract; col. 2 @ 30-40; col. 3 @ 23-63; col. 5 @ 21-36; col. 13 @ 46-64; col. 16 @ 23-46). As discussed, Soykan et al. disclose the claimed invention except for an alarm circuit.

Nappholz et al. teach patient self-treatment using an alarm for the purpose of making the patient aware when a condition exists that needs to be treated by medication. It would have been obvious to one having ordinary skill in the art at the time of the invention to have used an alarm in the Soykan et al. system in order to confirm the patient's self-diagnosis of angina and ensure the patient is not giving himself medication when it is not needed (col. 1 @ 5-10 and 44-54; col. 4 @ 18-21; col. 7 @ 12-25; col. 20 @ 18-38).

5. Claim 41 is rejected under 35 U.S.C. 103(a) as being unpatentable over Soykan et al. (US 6206914) in view of Nappholz et al. (US 5113869) and further in view of Guracar et al. (US 6086539). As discussed in paragraph 4 of this action, modified Soykan et al. disclose the claimed invention except for the signal being an integral.

Guracar et al. teach flow signal analysis using an integral for the purpose of showing change in the cardiac signal over time. It would have been obvious to one having ordinary skill in the art at the time of the invention to have used the intergral of the flow signal in the modified Soyken et al. system in order to accurately depict changes the cardiac cycle (col. 24 @ 7-12).

Art Unit: 3762

6. Claim 42 is rejected under 35 U.S.C. 103(a) as being unpatentable over Soykan et al. (US 6206914) in view of Nappholz et al. (US 5113869) and further in view of Guracar et al. (US 6086539) and further in view of Ferek-Petric et al. (US 5316001). As discussed in paragraphs 4 and 5 of this action, modified Soykan et al. disclose the claimed invention except for outputting a pacing stimuli.

Ferek-Petric et al. teach cardiac electrotherapy using pacing stimuli based on blood flow and electrical activity signals for the purpose of more accurately monitoring the cardiac activity. It would have been obvious to one having ordinary skill in the art at the time of the invention to have used pacing stimuli based on blood flow and electrical activity signals in the modified Soykan et al. system in order to achieve correspondingly improved pacing results (abstract; col. 9 @ 14-53).

Specification

7. The specification is objected to as failing to provide proper antecedent basis for the claimed subject matter. See 37 CFR 1.75(d)(1) and MPEP § 608.01(o). Correction of the following is required: The Examiner is unable to find in the specification the limitations in parenthesis: ...”mathematical” integral of “at least one of the blood flow signal and the sensed electrical signal”. New matter may not be added at this point in the prosecution. Appropriate correction is required.

Statutory Basis

8. The text of those sections of Title 35, U.S. Code not included in this action can be found in a prior Office action.

Conclusion

Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, **THIS ACTION IS MADE FINAL**. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the date of this final action.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Frances P. Oropeza whose telephone number is (571) 272-4953. The examiner can normally be reached Monday through Friday from 9 AM to 5:30 PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Angela D. Sykes, can be reached on (571) 272-4955. The telephone number for facsimiles for regular communication and After Final communications is (703) 872-9306.

Frances P. Oropeza
Patent Examiner
Art Unit 3762

FPO
2/13/05

Angela D. Sykes

ANGELA D. SYKES
SUPERVISORY PATENT EXAMINER
TECHNOLOGY CENTER 3700